Meeting
2015 ASCO Annual Meeting
Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA).
Authors
Daniela Matei
Indiana Univ Simon Cancer Ctr, Indianapolis, IN
Daniela Matei , Martin J. Edelman , Jasgit C. Sachdev , Patrick Klein , Satish Rao , Shelly Burgess , Romnee Clark , Ramesh K. Ramanathan , Elizabeth A Morris , Wael A. Harb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
001999738
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2551)
DOI
10.1200/jco.2015.33.15_suppl.2551
Abstract #
2551
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
First Author: Chao Hui Huang
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2018 ASCO Annual Meeting
Phase I trial of lurbinectedin (PM1183) in Japanese patients with advanced tumors: Results of the dose escalation part.
First Author: Shunji Takahashi